1. Home
  2. KPTI vs HIT Comparison

KPTI vs HIT Comparison

Compare KPTI & HIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • HIT
  • Stock Information
  • Founded
  • KPTI 2008
  • HIT 1964
  • Country
  • KPTI United States
  • HIT United States
  • Employees
  • KPTI N/A
  • HIT N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • HIT Specialty Insurers
  • Sector
  • KPTI Health Care
  • HIT Finance
  • Exchange
  • KPTI Nasdaq
  • HIT Nasdaq
  • Market Cap
  • KPTI 44.5M
  • HIT 157.9M
  • IPO Year
  • KPTI 2013
  • HIT 2024
  • Fundamental
  • Price
  • KPTI $7.11
  • HIT $2.76
  • Analyst Decision
  • KPTI Buy
  • HIT Strong Buy
  • Analyst Count
  • KPTI 6
  • HIT 1
  • Target Price
  • KPTI $39.80
  • HIT $2.50
  • AVG Volume (30 Days)
  • KPTI 218.0K
  • HIT 947.6K
  • Earning Date
  • KPTI 08-11-2025
  • HIT 07-21-2025
  • Dividend Yield
  • KPTI N/A
  • HIT N/A
  • EPS Growth
  • KPTI N/A
  • HIT N/A
  • EPS
  • KPTI N/A
  • HIT 0.02
  • Revenue
  • KPTI $137,269,000.00
  • HIT $26,692,318.00
  • Revenue This Year
  • KPTI $3.67
  • HIT $70.02
  • Revenue Next Year
  • KPTI $9.40
  • HIT $63.39
  • P/E Ratio
  • KPTI N/A
  • HIT $133.54
  • Revenue Growth
  • KPTI N/A
  • HIT 29.68
  • 52 Week Low
  • KPTI $3.51
  • HIT $0.51
  • 52 Week High
  • KPTI $16.95
  • HIT $7.59
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 66.00
  • HIT 55.13
  • Support Level
  • KPTI $6.02
  • HIT $2.72
  • Resistance Level
  • KPTI $8.15
  • HIT $3.60
  • Average True Range (ATR)
  • KPTI 0.74
  • HIT 0.41
  • MACD
  • KPTI 0.24
  • HIT -0.11
  • Stochastic Oscillator
  • KPTI 76.42
  • HIT 14.48

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About HIT Health In Tech Inc. Class A Common Stock

Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.

Share on Social Networks: